DOCSLIB.ORG

TNF-A Inhibitors and Efalizumab for the Treat- Ment of Skin Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TNF-A Inhibitors and Efalizumab for the Treat- Ment of Skin Diseases TNF-a inhibitors and efalizumab for the treat- ment of skin diseases This is an excerpt from the full technical report, which is written in Norwegian. The excerpt provides the report’s main messages in English. N0. 15–2007 Systematic reviews and health economic evaluation Title TNF-α inhibitors and efalizumab for the treatment of skin diseases Norwegian title TNF-hemmere og efaluzimab ved behandling av hudsykdommer Institution Norwegian Knowledge Centre for the Health Services (Nasjonalt kunnskapssenter for helsetjenesten) John-Arne Røttingen, Director Authors Ingvil Sæterdal, Researcher, (Project leader) Nils-Jørgen Mørk, Senior Consultant, (Professional manager) Morten Dalaker, Senior Consultant Tor Langeland, Dermatologist Erlend Tolaas, Senior Consultant Espen Movik, Health economist Jan Odgaard-Jensen, Statistician Anita Lyngstadaas, Senior Advisor Marianne Klemp Gjertsen, Research manager ISBN 978-82-8121-164-3 ISSN 1890-1298 Report No. 15 – 2007 Project number 353 Type of report Systematic reviews and health economic evaluation No. of pages 83 (137 incl. attachments) Client The Regional Health Authorities “Commissioners” Forum Subject heading Efalizumab; Skin Diseases; Tumor Necrosis Factor-alpha (MeSH) Citation Sæterdal I, Mørk NJ, Dalaker M, Langeland T, Tolaas E, Movik E, Odgaard- Jensen J, Lyngstadaas A, Gjertsen MK. TNF-α inhibitors and efalizumab for the treatment of skin diseases. Report from Kunnskapssenteret no. 15−2007. Oslo: Norwegian Knowledge Centre for the Health Services, 2007. Norwegian Knowledge Centre for the Health Services summarizes and disseminates evidence concerning the effect of treatments, methods, and interventions in health services, in addition to monitoring health service quality. Our goal is to support good decision making in order to provide patients in Norway with the best possible care. The Centre is organized under The Norwegian Directorate for Health, but is scientifically and professionally independent. The Centre has no authority to develop health policy or responsibility to implement policies. We would like to thank all contributers for their expertise in this project. Norwegian Knowledge Centre for the Health Services assumes final responsibility for the content of this report. Norwegian Knowledge Centre for the Health Services Oslo, May 2007 E Key messages ng li s h TNF-α inhibitors and efalizumab for the treatment of skin diseases Background: Skin diseases like psoriasis, pyoderma gangrenosum and Behçets disease are often chronic with the need for continuous treatment and follow-up. Traditional treatment like phototherapy or systemic therapy with ciclosporin, me- totrexate and retinoids are not always effective or cause long-term side effects. New bio- logical agents, which targets pathologic T cell activity, have been developed. This report deals with the biological agents’ tumour necrosis factor alpha (TNF-α) inhibitors (infliximab (Remicade®), adalimumab (Humira®), etanercept (Enbrel®) and efalizumab (Raptiva®) which is a T cell modulator. Methods: The systematic review was performed according to procedures described in the Norwegian Knowledge Centre for the Health Services’ handbook (1). The work was carried out together with a review team of external professionals. The literature was identified by a systematic search in electronic databases. The pharmaceutical companies were also invited to dispatch documentation. A health economic consideration based on available literature was written. Results: 26 publications were included in the report. 24 of the publications were on pso- riasis, one on pyoderma gangrenosum and one on Behçets disease. Sixteen of the studies are RCTs and ten are follow-up studies or separate publications of the included RCTs. The results show that both the TNF-α inhibitors and efalizumab are significantly more effec- tive than placebo for the treatment of moderate to severe psoriasis at week 10-12. The quality of life was also improved compared to placebo treatment. There is lack of RCTs concerning other skin diseases than psoriasis. Long term data for evaluation of adverse events were not identified, and conclusions regarding long-term safety cannot be drawn. Conclusions: There is good evidence that TNF-α inhibitors and efalizumab is efficacious in the treatment of moderate to severe psoriasis. We did not find studies comparing TNF- α inhibitors and efalizumab with traditional treatment. Limited data is available con- cerning safety in long-term use. One study on health economics performed in England indicates that etanercept and efal- izumab is cost-effective for patients with severe psoriasis and low quality of life that re- sponds well to the treatment. 6 E Executive summary ng li s h TNF-α inhibitors and efalizumab for the treatment of skin diseases BACKGROUND Skin diseases like psoriasis, pyoderma gangrenosum and Behçets disease are often chronic with the need for continuous treatment and follow-up. Recent research has shown that the immune system and T cells in particular, are impor- tant for the development of psoriasis. The plaques that characterise the most common form of psoriasis are often infiltrated with T cells The T cells initiate a complex process that leads to inflammation and over production of keratinocytes. The T cells produce tumour necrosis factor alpha (TNF-α) which plays an important role in the process. The cause of pyoderma gangrenosum and Behçets disease is unknown but we assume that they are immunomediated. Traditional treatment like phototherapy or systemic therapy with ciclosporin, me- totrexate and retinoids are not always effective or cause long-term side effects. This systematic review deals with the biological agents tumour necrosis factor alpha (TNF-α) inhibitors and efalizumab which all target pathologic T cell activity and is used for the treatment of inflammatory skin diseases. The TNF-α inhibitors comprise infliximab (Remicade®), adalimumab (Humira®) and etanercept (Enbrel®). Efalizumab (Raptiva®) is a T cell modulator. The primary outcomes in the review were efficacy and safety of the treatment. The effi- cacy was assessed by the proportion of patient’s achieving a 50, 75 or 90 % reduction in the Psoriasis Area Severity Index (PASI). The PASI is an assessment score, representing the extent, redness, thickness and scaliness of a person’s psoriasis on a single scale. Qual- ity of life was also considered. METHODS The systematic review was performed according to procedures described in the Norwe- gian Knowledge Centre for the Health Services’ handbook (1). The work was carried out together with a review team of external professionals. The literature was identified by a systematic search in electronic databases. The pharmaceutical companies were also in- vited to dispatch documentation. All identified publications were assessed for relevance according to predefined criteria. Quality of relevant publications was assessed by the use of checklists. 7 The results were summarized for the predefined outcomes and both as a descriptive summary and quantitatively with meta analysis. A health economic consideration based on available literature was written. RESULTS 26 publications were included in the report. 24 of the publications were on moderate to severe psoriasis, one on pyoderma gangrenosum and one on Behçets disease. Sixteen of the studies are RCTs and ten are follow-up studies or separate publications of the in- cluded RCTs. 4 studies for the health economic evaluation ere included. Our analysis shows that TNF-α inhibitors and efalizumab are significantly more effective than placebo for the treatment of psoriasis at week 10-12. This was assessed by PASI im- provement and reported for PASI 50, 75 and 90. Treatment of psoriasis using infliximab resulted in 70-88 % of patients in the study groups and 2-18 % in the control groups achieved PASI 75 at week 10. At week 12 achieved 53 % of the patients treated with adalimumab every second week, 80 % of the patients treated with adalimumab every week and 4 % of the patients receiving placebo 75 % improvement in PASI score. Treatment of psoriasis using etanercept resulted in achievement of PASI 75 with 14 - 49 % in the study groups and 2-5 % in the control groups at week 12. The results for achieving PASI 75 after treatment with efalizumab are 22–39 % in the study groups and 2–5 % in the control groups at week 12. The results are analysed independently of dose. The results show that TNF-α inhibitors and efalizumab significantly improves quality of life compared with placebo, assessed by improved DLQI (the Dermatology Life Quality Index). Due to limited safety data and short term studies, it is not possible to conclude on long- term safety issues. The included studies did not report on significant differences in ad- verse events between study group and control group. No studies (RCTs) comparing the different TNF-α infibitors were identified. Studies comparing TNF-α inhibitors or efalizumab with traditional treatment were also not found. Neither did we identify studies were TNF-α inhibitors or efalizumab were tested with and without co-treatment with an other immunosuppresive agent. There is also a need for long-term safety data. Relatively few health economic evaluations of TNF-α inhibitors for psoriasis were identi- fied. We included one study from the UK and three from the US. The UK study was based on a complex model, which showed that, in a 10-year perspective, treatment with etaner- cept and efalizumab are generally not cost-effective as treatment for the average psoria-
Load more

Recommended publications
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Study Protocol
    PROTOCOL SYNOPSIS A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus International Coordinating Investigator Study site(s) and number of subjects planned Approximately 450 subjects are planned at approximately 173 sites. Study period Phase of development Estimated date of first subject enrolled Q2 2015 3 Estimated date of last subject completed Q2 2018 Study design This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab (150 mg or 300 mg) versus placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age. Approximately 450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to receive a fixed intravenous dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous (IV) infusion via an infusion pump over a minimum of 30 minutes, Q4W. Subjects must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. Randomisation will be stratified using the following factors: SLE Disease Activity Index 2000 (SLEDAI-2K) score at screening (<10 points versus ≥10 points); Week 0 (Day 1) OCS dose 2(125) Revised Clinical Study Protocol Drug Substance Anifrolumab (MEDI-546) Study Code D3461C00005 Edition Number 5 Date 18 May 2016 (<10 mg/day versus ≥10 mg/day prednisone or equivalent); and results of a type 1 interferon (IFN) test (high versus low).
    [Show full text]
  • HLA-Cw6 Status Predicts Efficacy of Biologic Treatments in Psoriasis
    Global Dermatology Research Article ISSN: 2056-7863 HLA-Cw6 status predicts efficacy of biologic treatments in psoriasis patients Wayne P Gulliver1,2*, Heather Young1, Susanne Gulliver1 and Shane Randell1,2 1Newlab Clinical Research, St. John’s, NL, Canada 2Department of Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada Abstract Over the past decade, biologic therapies have been developed to treat auto-inflammatory conditions such as psoriasis. They have the advantage of better target specificity than traditional systemics such as methotrexate and cyclosporine and therefore significantly reduce side-effects and toxicity associated with wide spread systemic treatments. It has been suggested that the efficacy of biologics used in the treatment of psoriasis may be related with HLA-Cw6 status.Using HLA-Cw6 as a biomarker would therefore provide an advantage in the selection of a biologic agent for successful treatment based on a patient’s genetic makeup and thus allowing us to use HLA-Cw6 to individualize therapy for patients with moderate-to-severe psoriasis.In the present study, the HLA-Cw6 status was determined for psoriasis patients previously treated with etanercept, adalimumab, efalizumab, infliximab or ustekinumab.The success or failure rates of the biologic treatments were compared for patients with and without the HLA-Cw6 allele.The HLA-Cw6 status was significantly associated to the treatment outcomes for biologics efalizumab (no longer on the market), infliximab and ustekinumab; but not etanercept or adalimumab.These results support the use of HLA-Cw6 status as a biomarker for biologic treatment in moderate-to-severe psoriasis patients. Introduction The association appears strong and is found in anywhere from 40- 80% of cases [9], however other genes nearby may play a role that also Psoriasis vulgaris is a chronic inflammatory skin disease that contribute to the development of psoriasis.
    [Show full text]
  • Omalizumab Treatment in Severe Adult Atopic Dermatitis
    Case report Omalizumab treatment in severe adult atopic dermatitis Supitchaya Thaiwat1 and Atik Sangasapaviliya2 Summary Conventional therapies for AD include topical Atopic dermatitis (AD) is one of the most agents e.g., steroids, topical calcineurin inhibitors, common chronic skin diseases. Treatment phototherapy and oral medications e.g. azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, options include lubricants, antihistamines, and 4 corticosteroids in either topical or oral forms. prednisone, etc. Oral medications are generally Severe AD is frequently recalcitrant to these reserved for moderate to severe AD because of their medications. We reported three cases of severe systemic toxicities e.g., adrenal suppression, AD patients who had elevated of IgE levels and diabetes, renal toxicity, liver toxicity and failed to response to several prior medical myelosuppression. treatment. Omalizumab is a humanized monoclonal anti- After being treated with Omalizumab IgE antibody that binds to the IgE molecule at the (humanized monoclonal anti-IgE antibody), the high-affinity FcεRI receptor binding site. The drug patients had marked alleviation of symptoms has been approved by the Food and Drug with improved Eczema Area and Severity Index Administration for adults and adolescents (12 years of age and above) with moderate to severe persistent (EASI) and pruritic scores. No patient 5 experienced adverse effect. (Asian Pac J Allergy asthma Since AD shares a common pathologic Immunol 2011;29:357-60) mechanism, that is IgE reactivation, with asthma, omalizumab has been tested as a systemic therapy Key words: Omalizumab, IgE levels, EASI score for recalcitrant AD associated with elevated IgE levels. We reported three cases of severe AD in Introduction adults who were successfully treated with Atopic dermatitis (AD) is one of the most Omalizumab.
    [Show full text]
  • Progressive Multifocal Leukoencephalopathy and the Spectrum of JC Virus-​Related Disease
    REVIEWS Progressive multifocal leukoencephalopathy and the spectrum of JC virus- related disease Irene Cortese 1 ✉ , Daniel S. Reich 2 and Avindra Nath3 Abstract | Progressive multifocal leukoencephalopathy (PML) is a devastating CNS infection caused by JC virus (JCV), a polyomavirus that commonly establishes persistent, asymptomatic infection in the general population. Emerging evidence that PML can be ameliorated with novel immunotherapeutic approaches calls for reassessment of PML pathophysiology and clinical course. PML results from JCV reactivation in the setting of impaired cellular immunity, and no antiviral therapies are available, so survival depends on reversal of the underlying immunosuppression. Antiretroviral therapies greatly reduce the risk of HIV-related PML, but many modern treatments for cancers, organ transplantation and chronic inflammatory disease cause immunosuppression that can be difficult to reverse. These treatments — most notably natalizumab for multiple sclerosis — have led to a surge of iatrogenic PML. The spectrum of presentations of JCV- related disease has evolved over time and may challenge current diagnostic criteria. Immunotherapeutic interventions, such as use of checkpoint inhibitors and adoptive T cell transfer, have shown promise but caution is needed in the management of immune reconstitution inflammatory syndrome, an exuberant immune response that can contribute to morbidity and death. Many people who survive PML are left with neurological sequelae and some with persistent, low-level viral replication in the CNS. As the number of people who survive PML increases, this lack of viral clearance could create challenges in the subsequent management of some underlying diseases. Progressive multifocal leukoencephalopathy (PML) is for multiple sclerosis. Taken together, HIV, lymphopro- a rare, debilitating and often fatal disease of the CNS liferative disease and multiple sclerosis account for the caused by JC virus (JCV).
    [Show full text]
  • Greenwald's Law of Lupus
    A Mashup of Instructive Cases Presenting With Subacute Cutaneous LE (SCLE) Skin Lesions Medical Dermatology Society Denver, Colorado March 20, 2014 Rick Sontheimer, M.D. Professor of Dermatology University of Utah School of Medicine Potential Conflicts of Interest March, 2014 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest Therapeutics • Royalties – P&G (ChelaDerm) – Lippincott, – Celgene Williams – Sanofi & Wilkins • Research collaboration – 3Gen, LLT Gilliam JN:: The cutaneous signs of lupus erythematosus. Continuing Education for the Family Physician 1977; 6:34 “Subacute cutaneous lupus erythematosus” 38 yrs of SCLE The First Two Decades: 1979-1996 Dallas • Prognostic significance of SCLE lesional morphology and anatomic distribution • SCLE and “pseudolupus” • SjS complicating SCLE SCLE Papulosquamous Annular (Psoriasiform Array) (Polycyclic array) Risk of Systemically- Significant SLE in SCLE < Relative Sparing of Central Face Risk Factors SCLE Clinically-Significant SLE (?) • Papulosquamous/ • Resistance to psoriasiform antimalarials morphology • Leukopenia • Central facial • High titer ANA involvement • Circulating dsDNA (ACLE) antibodies SCLE and “Pseudolupus” Dallas – 1990s Greenwald’s Law of Lupus Greenwald RA. Greenwald's law of lupus. J Rheumatol. 1992 Sep;19(9):1490. “…anything happening to a patient with SLE which is not immediately otherwise
    [Show full text]
  • Efalizumab Binding to the LFA-1 L I Domain Blocks ICAM-1 Binding Via
    Efalizumab binding to the LFA-1 ␣L I domain blocks ICAM-1 binding via steric hindrance Sheng Lia,1, Hao Wangb,1, Baozhen Penga, Meilan Zhanga, Daipong Zhangb, Sheng Houb, Yajun Guob,2, and Jianping Dinga,2 aState Key Laboratory of Molecular Biology and Research Center for Structural Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China; and bInternational Joint Cancer Institute, Second Military Medical University, 800 Xiang-Yin Road, Shanghai 200433, China Edited by Timothy A. Springer, Harvard Medical School, Boston, MA, and approved January 26, 2009 (received for review October 28, 2008) Lymphocyte function-associated antigen 1 (LFA-1) plays important matory diseases and is implicated in multiple cancers including roles in immune cell adhesion, trafficking, and activation and is a myeloma, malignant lymphoma, and acute and chronic leukemias therapeutic target for the treatment of multiple autoimmune dis- (21–25). Thus, it has become a therapeutic target for the treatment eases. Efalizumab is one of the most efficacious antibody drugs for of multiple autoimmune and inflammatory diseases and cancers (8, treating psoriasis, a very common skin disease, through inhibition of 26, 27). Psoriasis is a very common skin disease that is characterized the binding of LFA-1 to the ligand intercellular adhesion molecule 1 by red or salmon pink color, white or silver scaly and raised plaques (ICAM-1). We report here the crystal structures of the Efalizumab Fab (22). Although the cause of psoriasis remains an enigma, it has become increasingly clear that the activity of the lymphocytic alone and in complex with the LFA-1 ␣L I domain, which reveal the molecular mechanism of inhibition of LFA-1 by Efalizumab.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • A Decade of Natalizumab and PML: Has There Been a Tacit Transfer of Risk Acceptance?
    A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance? David B. Clifford1, Tarek A. Yousry2, and Eugene O. Major3 1. Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA 2. UCL Institute of Neurology, Neuroradiology Academic Unit, Queen Square, London, UK 3. Division of NeuroImmunology and NeuroVirology, NINDS, NIH , Bethesda, MD, USA Corresponding author: Dr Eugene O Major, [email protected] All authors participated equally Key Words: Natalizumab, PML risk, stakeholders Abstract The interplay between each of these stakeholder’s responsibilities and desires clearly has resulted in continued widespread use of natalizumab with substantial risks and an ongoing quest for better risk mitigation. In the United States, regulatory actions codified the process of risk acceptance – and risk transfer- by escalating monitoring and information transfer to physicians and patients through Management of medication related risks is a core function of regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA) and the medical community. The interplay between stakeholders in medicine, pharma, regulatory bodies, physicians and patients, sometimes has changed without overt review and discussion. Such is the case for natalizumab, an important and widely used disease modifying therapy for multiple sclerosis. A rather silent but very considerable shift, effectively transferring increased risk for PML to the physicians and patients, has occurred in the past decade. We believe this changed risk should be clearly recognized and considered by all the stakeholders. History of natalizumab and Multiple Sclerosis The authors led the first assessment of the risk of natalizumab associated PML as an Independent Adjudication Committee organized to screen research patients exposed to natalizumab.
    [Show full text]
  • Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-Ige Syndrome
    Hindawi Case Reports in Immunology Volume 2019, Article ID 6357256, 5 pages https://doi.org/10.1155/2019/6357256 Case Report Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome Cesar Daniel Alonso-Bello ,1 Mar-a del Carmen Jiménez-Mart-nez ,2 Mar-a Eugenia Vargas-Camaño,1 Sagrario Hierro-Orozco,3 Mario Alberto Ynga-Durand ,4,5 Laura Berrón-Ruiz,6 Julio César Alcántara-Montiel,4 Leopoldo Santos-Argumedo,7 Diana Andrea Herrera-Sánchez,1 Fernando Lozano-Patiño,1 and Mar-a Isabel Castrejón-Vázquez 1 1 Immunology and Allergy Department, Centro Medico´ Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico 2Faculty of Medicine, Universidad Nacional Autonoma´ de Mexico,´ Mexico 3Dermatology Department, Centro Medico´ Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico 4Universidad Nacional Autonoma´ de Mexico,´ Facultad de Estudios Superiores Zaragoza, Facultad de Medicina, Mexico 5Laboratorio de Inmunidad de Mucosas, Seccion´ de Investigacion´ y Posgrado, Escuela Superior de Medicina, Instituto Politecnico´ Nacional, Mexico City, Mexico 6Immunodefciencies Research Unit, Instituto Nacional de Pediatria, Secretar´ıa de Salud, Mexico 7Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico Correspondence should be addressed to Cesar Daniel Alonso-Bello; cesar [email protected] Received 21 April 2019; Accepted 13 June 2019; Published 4 July 2019 Academic Editor: Necil K¨ut¨ukc¸¨uler Copyright © 2019 Cesar Daniel Alonso-Bello et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Immunopharmacology: a Guide to Novel Therapeutic Tools - Francesco Roselli, Emilio Jirillo
    PHARMACOLOGY – Vol. II - Immunopharmacology: A Guide to Novel Therapeutic Tools - Francesco Roselli, Emilio Jirillo IMMUNOPHARMACOLOGY: A GUIDE TO NOVEL THERAPEUTIC TOOLS Francesco Roselli Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy Emilio Jirillo Department of Internal Medicine, Immunology and Infectious Disease, University of Bari, Italy National Institute for Digestive Disease, Castellana Grotte, Bari, Italy Keywords: Immunopharmacology, immunosuppressive agents, immunomodulating agents, Rituximab, Natalizumab, Efalizumab, Abatacept, Betalacept, Alefacept, Basiliximab, Daclizumab, Infliximab, Etanercept, Adalimumab, Anakinra, Tocilizumab, Omalizumab, Interleukin-2, Denileukin diftitox, Interferon-γ, Interleukin-12 Contents 1. Introduction 2. B cell targeted molecule: Rituximab 3. Lymphocyte trafficking inhibitors: Natalizumab and Efalizumab 3.1 Natalizumab 3.2 Efalizumab 4. Costimulation antagonists: Abatacept, Betalacept, Alefacept 4.1 Abatacept 4.2 Betalacept 4.3 Alefacept 5. Interleukin-2 Receptor antagonists: Basiliximab, Daclizumab 5.1 Basiliximab 5.2 Daclizumab 6. Antagonists of soluble mediators of inflammation 6.1 TNF-α antagonists: Infliximab, Etanercept, Adalimumab 6.1.1 Infliximab 6.1.2 Etanercept 6.1.3 Adalimumab 6.2 Interleukin-1UNESCO Receptor Antagonist (Anakinra) – EOLSS 6.3 Interleukin-6 receptor antagonist (tocilizumab) 7. Antagonist of IgE: Omalizumab 8. Interleukin therapySAMPLE in oncology CHAPTERS 8.1 Interleukin-2 8.2 Interleukin-2/diphtheria toxin conjugate (Ontak) 8.3 Interferon-γ and Interleukin-12 9. Perspectives and future developments Glossary Bibliography Biographical Sketches Summary ©Encyclopedia of Life Support Systems (EOLSS) PHARMACOLOGY – Vol. II - Immunopharmacology: A Guide to Novel Therapeutic Tools - Francesco Roselli, Emilio Jirillo Immunopharmacology is that area of pharmacological sciences dealing with the selective modulation (i.e. upregulation or downregulation) of specific immune responses and, in particular, of immune cell subsets.
    [Show full text]
  • A1089-Anti-Cd11a (Efalizumab)
    BioVision rev.11/17 For research use only Anti-CD11a (Efalizumab), Human IgG1 Antibody CATALOG NO: A1089-200 ALTERNATIVE NAMES: LFA-1; integrin alpha L AMOUNT: 200 µg IMMUNOGEN: Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. ISOTYPE /FORMAT: Human IgG1, kappa CLONALITY: Monoclonal CLONE: hu1124 SPECIES REACTIVITY: Human Flow-cytometry using the anti-CD11a research biosimilar antibody Efalizumab: Human lymphocytes were stained with an isotype control or the rabbit-chimeric version of FORM: Liquid Efalizumab at a concentration of 1 µg/ml for 30 mins at RT. After washing, bound antibody was detected using AF488 conjugated donkey anti-rabbit antibody and analyzed on a PURIFICATION: Affinity purified using Protein A FACSCanto flow-cytometer. FORMULATION: Supplied in PBS with preservative (0.02% Proclin 300) RELATED PRODUCTS: STORAGE CONDITIONS: Store at 4°C for upto 3 months. For long term storage, aliquot and freeze at -20°C. Avoid repeated freeze/defrost cycles. Anti-VEGF (Bevacizumab), humanized Antibody (Cat. No. A1045-100) Anti-HER2 (Trastuzumab), humanized Antibody (Cat. No. A1046-100) DESCRIPTION: Recombinant monoclonal antibody to CD11a. Manufactured using recombinant technology with variable regions (i.e. specificity) from Anti-EGFR (Cetuximab), Chimeric Antibody (Cat. No. A1047-100) the therapeutic antibody hu1124 (Efalizumab). Anti-TNF-α (Adalimumab), humanized Antibody (Cat. No. A1048-100) BACKGROUND: Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 Anti-CD20 (Rituximab), Chimeric Antibody (Cat. No. A1049-100) and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell Anti-EGFR (Panitumumab), humanized antibody (Cat.
    [Show full text]